Antihypertensives and COVID-19: Literature review
Autor(a) principal: | |
---|---|
Data de Publicação: | 2021 |
Outros Autores: | , , , , , , |
Tipo de documento: | Artigo |
Idioma: | eng |
Título da fonte: | Research, Society and Development |
Texto Completo: | https://rsdjournal.org/index.php/rsd/article/view/15977 |
Resumo: | Hypertensive patients with COVID-19 are susceptible to complications of the disease, so this study aimed to analyze the action of drugs that act on Angiotensin (TA) in the presence of COVID-19 in comparison with other antihypertensives, as well as to identify the main ones. evidence on the subject presented so far. It is an integrative literature review containing 34 articles selected according to the inclusion criteria, between January / 2020 to February / 2021, in the PubMed, Embase, Scopus and Web of Science databases. The results do not show a causal relationship between the increase in COVID-19 infection and the use of RAAS inhibitors, but a possible protective effect of these against the severe manifestation of the disease due to the inhibition of the pro-inflammatory diseases of AT II. Thus, about ⅔ of the studies defended the continuity of use and the protection factor of RAAS blockers to the detriment of the other classes of antihypertensive drugs that do not modulate RAAS. It was found, then, that antihypertensive treatment should be maintained, as it does not worsen the prognosis in the face of Sars-CoV-2 infection. However, the studies are mainly observational and, therefore, cannot establish strong causal relationships. For this reason, robust randomized controlled trials are needed to better understand this topic. |
id |
UNIFEI_59181dc9b911506878bcdb9244f5016b |
---|---|
oai_identifier_str |
oai:ojs.pkp.sfu.ca:article/15977 |
network_acronym_str |
UNIFEI |
network_name_str |
Research, Society and Development |
repository_id_str |
|
spelling |
Antihypertensives and COVID-19: Literature reviewAntihipertensivos y COVID-19: Revisión de la literaturaAnti-hipertensivos e COVID-19: Revisão de literaturaAntihypertensive AgentsAngiotensin-Converting Enzyme InhibitorsHypertensionSARS-CoV-2COVID-19.Agentes AntihipertensivosInhibidores de la Enzima Convertidora de AngiotensinaHipertensiónSARS-CoV-2COVID-19.Anti-hipertensivosInibidores da Enzima Conversora da AngiotensinaHipertensãoSARS-CoV-2COVID-19.Hypertensive patients with COVID-19 are susceptible to complications of the disease, so this study aimed to analyze the action of drugs that act on Angiotensin (TA) in the presence of COVID-19 in comparison with other antihypertensives, as well as to identify the main ones. evidence on the subject presented so far. It is an integrative literature review containing 34 articles selected according to the inclusion criteria, between January / 2020 to February / 2021, in the PubMed, Embase, Scopus and Web of Science databases. The results do not show a causal relationship between the increase in COVID-19 infection and the use of RAAS inhibitors, but a possible protective effect of these against the severe manifestation of the disease due to the inhibition of the pro-inflammatory diseases of AT II. Thus, about ⅔ of the studies defended the continuity of use and the protection factor of RAAS blockers to the detriment of the other classes of antihypertensive drugs that do not modulate RAAS. It was found, then, that antihypertensive treatment should be maintained, as it does not worsen the prognosis in the face of Sars-CoV-2 infection. However, the studies are mainly observational and, therefore, cannot establish strong causal relationships. For this reason, robust randomized controlled trials are needed to better understand this topic.Los pacientes hipertensos con COVID-19 son susceptibles a complicaciones de la enfermedad, por lo que este estudio tuvo como objetivo analizar la acción de los fármacos que actúan sobre la Angiotensina (TA) en presencia de COVID-19 en comparación con otros antihipertensivos, así como identificar la los principales. evidencia sobre el tema presentado hasta ahora. Se trata de una revisión integradora de la literatura que contiene 34 artículos seleccionados según los criterios de inclusión, entre enero / 2020 a febrero / 2021, en las bases de datos PubMed, Embase, Scopus y Web of Science. Los resultados no muestran una relación causal entre el aumento de la infección por COVID-19 y el uso de inhibidores del RAAS, sino un posible efecto protector de estos frente a la manifestación grave de la enfermedad debido a la inhibición de las enfermedades proinflamatorias de AT II. Así, aproximadamente la cuarta parte de los estudios defendieron la continuidad del uso y el factor de protección de los bloqueadores de RAAS en detrimento de las otras clases de fármacos antihipertensivos que no modulan el RAAS. Se constató, entonces, que se debe mantener el tratamiento antihipertensivo, ya que no empeora el pronóstico ante la infección por Sars-CoV-2. Sin embargo, los estudios son principalmente observacionales y, por lo tanto, no pueden establecer relaciones causales sólidas. Por esta razón, se necesitan ensayos controlados aleatorios sólidos para comprender mejor este tema.Pacientes hipertensos com COVID-19 são suscetíveis às complicações da doença, portanto este estudo teve como objetivo analisar a ação de fármacos que atuam sobre a Angiotensina (AT) na presença de COVID-19 em comparação com outros anti-hipertensivos, bem como identificar os principais. evidências sobre o assunto apresentadas até o momento. Trata-se de uma revisão integrativa da literatura contendo 34 artigos selecionados segundo os critérios de inclusão, entre janeiro / 2020 a fevereiro / 2021, nas bases de dados PubMed, Embase, Scopus e Web of Science. Os resultados não mostram uma relação causal entre o aumento da infecção por COVID-19 e o uso de inibidores do RAAS, mas um possível efeito protetor destes contra a manifestação grave da doença devido à inibição das doenças pró-inflamatórias do AT II. Assim, cerca de ⅔ dos estudos defenderam a continuidade do uso e o fator de proteção dos bloqueadores RAAS em detrimento das demais classes de anti-hipertensivos que não modulam o RAAS. Verificou-se, então, que o tratamento anti-hipertensivo deve ser mantido, pois não piora o prognóstico diante da infecção pelo Sars-CoV-2. No entanto, os estudos são principalmente observacionais e, portanto, não podem estabelecer relações causais fortes. Por esse motivo, ensaios clínicos randomizados robustos são necessários para melhor compreender este tópico.Research, Society and Development2021-06-04info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionapplication/pdfhttps://rsdjournal.org/index.php/rsd/article/view/1597710.33448/rsd-v10i6.15977Research, Society and Development; Vol. 10 No. 6; e41510615977Research, Society and Development; Vol. 10 Núm. 6; e41510615977Research, Society and Development; v. 10 n. 6; e415106159772525-3409reponame:Research, Society and Developmentinstname:Universidade Federal de Itajubá (UNIFEI)instacron:UNIFEIenghttps://rsdjournal.org/index.php/rsd/article/view/15977/14252Copyright (c) 2021 Thais Cristina Loyola da Silva; Pedro Vilar de Oliveira Villarim; Alyne Barreto Mesquita de Goés; Vitória Ribeiro Dantas Marinho; Natália Marcelino Araújo; André Luiz Costa e Silva; Amália Cinthia Meneses Rêgo; Irami Araújo-Filhohttps://creativecommons.org/licenses/by/4.0info:eu-repo/semantics/openAccessSilva, Thais Cristina Loyola da Villarim, Pedro Vilar de Oliveira Goés, Alyne Barreto Mesquita de Marinho, Vitória Ribeiro Dantas Araújo, Natália Marcelino Silva, André Luiz Costa eRêgo, Amália Cinthia Meneses Araújo-Filho, Irami 2021-06-10T22:51:46Zoai:ojs.pkp.sfu.ca:article/15977Revistahttps://rsdjournal.org/index.php/rsd/indexPUBhttps://rsdjournal.org/index.php/rsd/oairsd.articles@gmail.com2525-34092525-3409opendoar:2024-01-17T09:36:40.310298Research, Society and Development - Universidade Federal de Itajubá (UNIFEI)false |
dc.title.none.fl_str_mv |
Antihypertensives and COVID-19: Literature review Antihipertensivos y COVID-19: Revisión de la literatura Anti-hipertensivos e COVID-19: Revisão de literatura |
title |
Antihypertensives and COVID-19: Literature review |
spellingShingle |
Antihypertensives and COVID-19: Literature review Silva, Thais Cristina Loyola da Antihypertensive Agents Angiotensin-Converting Enzyme Inhibitors Hypertension SARS-CoV-2 COVID-19. Agentes Antihipertensivos Inhibidores de la Enzima Convertidora de Angiotensina Hipertensión SARS-CoV-2 COVID-19. Anti-hipertensivos Inibidores da Enzima Conversora da Angiotensina Hipertensão SARS-CoV-2 COVID-19. |
title_short |
Antihypertensives and COVID-19: Literature review |
title_full |
Antihypertensives and COVID-19: Literature review |
title_fullStr |
Antihypertensives and COVID-19: Literature review |
title_full_unstemmed |
Antihypertensives and COVID-19: Literature review |
title_sort |
Antihypertensives and COVID-19: Literature review |
author |
Silva, Thais Cristina Loyola da |
author_facet |
Silva, Thais Cristina Loyola da Villarim, Pedro Vilar de Oliveira Goés, Alyne Barreto Mesquita de Marinho, Vitória Ribeiro Dantas Araújo, Natália Marcelino Silva, André Luiz Costa e Rêgo, Amália Cinthia Meneses Araújo-Filho, Irami |
author_role |
author |
author2 |
Villarim, Pedro Vilar de Oliveira Goés, Alyne Barreto Mesquita de Marinho, Vitória Ribeiro Dantas Araújo, Natália Marcelino Silva, André Luiz Costa e Rêgo, Amália Cinthia Meneses Araújo-Filho, Irami |
author2_role |
author author author author author author author |
dc.contributor.author.fl_str_mv |
Silva, Thais Cristina Loyola da Villarim, Pedro Vilar de Oliveira Goés, Alyne Barreto Mesquita de Marinho, Vitória Ribeiro Dantas Araújo, Natália Marcelino Silva, André Luiz Costa e Rêgo, Amália Cinthia Meneses Araújo-Filho, Irami |
dc.subject.por.fl_str_mv |
Antihypertensive Agents Angiotensin-Converting Enzyme Inhibitors Hypertension SARS-CoV-2 COVID-19. Agentes Antihipertensivos Inhibidores de la Enzima Convertidora de Angiotensina Hipertensión SARS-CoV-2 COVID-19. Anti-hipertensivos Inibidores da Enzima Conversora da Angiotensina Hipertensão SARS-CoV-2 COVID-19. |
topic |
Antihypertensive Agents Angiotensin-Converting Enzyme Inhibitors Hypertension SARS-CoV-2 COVID-19. Agentes Antihipertensivos Inhibidores de la Enzima Convertidora de Angiotensina Hipertensión SARS-CoV-2 COVID-19. Anti-hipertensivos Inibidores da Enzima Conversora da Angiotensina Hipertensão SARS-CoV-2 COVID-19. |
description |
Hypertensive patients with COVID-19 are susceptible to complications of the disease, so this study aimed to analyze the action of drugs that act on Angiotensin (TA) in the presence of COVID-19 in comparison with other antihypertensives, as well as to identify the main ones. evidence on the subject presented so far. It is an integrative literature review containing 34 articles selected according to the inclusion criteria, between January / 2020 to February / 2021, in the PubMed, Embase, Scopus and Web of Science databases. The results do not show a causal relationship between the increase in COVID-19 infection and the use of RAAS inhibitors, but a possible protective effect of these against the severe manifestation of the disease due to the inhibition of the pro-inflammatory diseases of AT II. Thus, about ⅔ of the studies defended the continuity of use and the protection factor of RAAS blockers to the detriment of the other classes of antihypertensive drugs that do not modulate RAAS. It was found, then, that antihypertensive treatment should be maintained, as it does not worsen the prognosis in the face of Sars-CoV-2 infection. However, the studies are mainly observational and, therefore, cannot establish strong causal relationships. For this reason, robust randomized controlled trials are needed to better understand this topic. |
publishDate |
2021 |
dc.date.none.fl_str_mv |
2021-06-04 |
dc.type.driver.fl_str_mv |
info:eu-repo/semantics/article info:eu-repo/semantics/publishedVersion |
format |
article |
status_str |
publishedVersion |
dc.identifier.uri.fl_str_mv |
https://rsdjournal.org/index.php/rsd/article/view/15977 10.33448/rsd-v10i6.15977 |
url |
https://rsdjournal.org/index.php/rsd/article/view/15977 |
identifier_str_mv |
10.33448/rsd-v10i6.15977 |
dc.language.iso.fl_str_mv |
eng |
language |
eng |
dc.relation.none.fl_str_mv |
https://rsdjournal.org/index.php/rsd/article/view/15977/14252 |
dc.rights.driver.fl_str_mv |
https://creativecommons.org/licenses/by/4.0 info:eu-repo/semantics/openAccess |
rights_invalid_str_mv |
https://creativecommons.org/licenses/by/4.0 |
eu_rights_str_mv |
openAccess |
dc.format.none.fl_str_mv |
application/pdf |
dc.publisher.none.fl_str_mv |
Research, Society and Development |
publisher.none.fl_str_mv |
Research, Society and Development |
dc.source.none.fl_str_mv |
Research, Society and Development; Vol. 10 No. 6; e41510615977 Research, Society and Development; Vol. 10 Núm. 6; e41510615977 Research, Society and Development; v. 10 n. 6; e41510615977 2525-3409 reponame:Research, Society and Development instname:Universidade Federal de Itajubá (UNIFEI) instacron:UNIFEI |
instname_str |
Universidade Federal de Itajubá (UNIFEI) |
instacron_str |
UNIFEI |
institution |
UNIFEI |
reponame_str |
Research, Society and Development |
collection |
Research, Society and Development |
repository.name.fl_str_mv |
Research, Society and Development - Universidade Federal de Itajubá (UNIFEI) |
repository.mail.fl_str_mv |
rsd.articles@gmail.com |
_version_ |
1797052678933577728 |